Anaconda BioMed

Anaconda Biomed is a Spanish medical device innovator developing the ANA thrombectomy system, a novel catheter designed to improve the safety and efficacy of mechanical thrombectomy for stroke. Its core technology features a self-expanding, flow-restricting nitinol funnel that aims to reduce clot fragmentation and embolization during retrieval. The company's lead product, the ANA5 Funnel Catheter, has CE mark approval in Europe and is in the investigational stage in the United States, positioning it in the high-growth neurovascular intervention market.

The ANA thrombectomy platform centers on a unique catheter with a self-expanding, nitinol-braided funnel covered in silicone. When deployed, it provides temporary flow restriction in the artery to support clot attachment to retrieval devices, aims to generate strong aspiration force, and protects the clot during retrieval to reduce fragmentation and distal embolization.

Anaconda competes in the crowded neurovascular thrombectomy device market against giants like Medtronic, Stryker, Johnson & Johnson, and Penumbra. Its strategy is not to replace existing stent retrievers but to enhance their performance with its funnel catheter, positioning it as a complementary tool within the standard combined technique.